Literature DB >> 11917103

Vav3 is regulated during the cell cycle and effects cell division.

Keiko Fujikawa1, Yoshiro Inoue, Masaharu Sakai, Yoshikazu Koyama, Shinzo Nishi, Ryo Funada, Frederick W Alt, Wojciech Swat.   

Abstract

Vav3 is a member of the family of guanine nucleotide exchange factors implicated in the regulation of Rho GTPases. Although the exact in vivo function of Vav3 is unknown, evidence from several studies indicates a role distinct from Vav2 or Vav1. Here we report that the expression of Vav3 is regulated during the cell cycle. Strikingly, Vav3 was transiently up-regulated in HeLa cells during mitosis, whereas enforced expression of Vav3 perturbed cytokinesis and led to the appearance of multinucleated cells. These effects of Vav3 were RhoA-dependent, required phosphorylation of the regulatory tyrosine 173, but were not enhanced by N-terminal truncations. Thus, this report establishes that expression of Vav3 is strictly regulated in a cell cycle-dependent manner and implicates Vav3 in the control of cytokinesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917103      PMCID: PMC123645          DOI: 10.1073/pnas.052715699

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 2.  Ras and Rho GTPases: a family reunion.

Authors:  D Bar-Sagi; A Hall
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody.

Authors:  K Hirose; T Kawashima; I Iwamoto; T Nosaka; T Kitamura
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

4.  Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling.

Authors:  K Tedford; L Nitschke; I Girkontaite; A Charlesworth; G Chan; V Sakk; M Barbacid; K D Fischer
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

5.  Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.

Authors:  L Zeng; P Sachdev; L Yan; J L Chan; T Trenkle; M McClelland; J Welsh; L H Wang
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  Signal transduction through Vav-2 participates in humoral immune responses and B cell maturation.

Authors:  G M Doody; S E Bell; E Vigorito; E Clayton; S McAdam; R Tooze; C Fernandez; I J Lee; M Turner
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

7.  Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins.

Authors:  N Movilla; X R Bustelo
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

8.  Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation.

Authors:  B Aghazadeh; W E Lowry; X Y Huang; M K Rosen
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

9.  Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav.

Authors:  A Tarakhovsky; M Turner; S Schaal; P J Mee; L P Duddy; K Rajewsky; V L Tybulewicz
Journal:  Nature       Date:  1995-03-30       Impact factor: 49.962

10.  vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells.

Authors:  S Katzav; D Martin-Zanca; M Barbacid
Journal:  EMBO J       Date:  1989-08       Impact factor: 11.598

View more
  12 in total

1.  Small interfering RNAs as a tool to assign Rho GTPase exchange-factor function in vivo.

Authors:  Alexandra Gampel; Harry Mellor
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

Review 2.  The Vav family: at the crossroads of signaling pathways.

Authors:  Wojciech Swat; Keiko Fujikawa
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

3.  Novel functions of Ect2 in polar lamellipodia formation and polarity maintenance during "contractile ring-independent" cytokinesis in adherent cells.

Authors:  Masamitsu Kanada; Akira Nagasaki; Taro Q P Uyeda
Journal:  Mol Biol Cell       Date:  2007-10-17       Impact factor: 4.138

Review 4.  Rho GTPases in animal cell cytokinesis: an occupation by the one percent.

Authors:  Shawn N Jordan; Julie C Canman
Journal:  Cytoskeleton (Hoboken)       Date:  2012-10-09

5.  Distinct gene expression profiles in immortalized human urothelial cells exposed to inorganic arsenite and its methylated trivalent metabolites.

Authors:  Pei-Fen Su; Yu-Jie Hu; I-Ching Ho; Yang-Ming Cheng; Te-Chang Lee
Journal:  Environ Health Perspect       Date:  2006-03       Impact factor: 9.031

6.  Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells.

Authors:  Keiko Fujikawa; Ana V Miletic; Frederick W Alt; Roberta Faccio; Tracie Brown; Jeremy Hoog; Jessica Fredericks; Shinzo Nishi; Shirly Mildiner; Sheri L Moores; Joan Brugge; Fred S Rosen; Wojciech Swat
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

7.  VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characterization.

Authors:  Yih-Huei Uen; Chia-Lang Fang; You-Cheng Hseu; Pei-Chun Shen; Hsin-Ling Yang; Kuo-Shan Wen; Shih-Ting Hung; Lu-Hai Wang; Kai-Yuan Lin
Journal:  Sci Rep       Date:  2015-03-20       Impact factor: 4.379

8.  MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer.

Authors:  Chien-Yu Cho; Kuo-Ting Lee; Wei-Ching Chen; Chih-Yang Wang; Yung-Sheng Chang; Hau-Lun Huang; Hui-Ping Hsu; Meng-Chi Yen; Ming-Zong Lai; Ming-Derg Lai
Journal:  Oncotarget       Date:  2016-03-22

9.  p190RhoGAP is cell cycle regulated and affects cytokinesis.

Authors:  Ling Su; Joyce M Agati; Sarah J Parsons
Journal:  J Cell Biol       Date:  2003-11-10       Impact factor: 10.539

10.  VAV3 mediates resistance to breast cancer endocrine therapy.

Authors:  Helena Aguilar; Ander Urruticoechea; Pasi Halonen; Kazuma Kiyotani; Taisei Mushiroda; Xavier Barril; Jordi Serra-Musach; Abul Islam; Livia Caizzi; Luciano Di Croce; Ekaterina Nevedomskaya; Wilbert Zwart; Josefine Bostner; Elin Karlsson; Gizeh Pérez Tenorio; Tommy Fornander; Dennis C Sgroi; Rafael Garcia-Mata; Maurice P H M Jansen; Nadia García; Núria Bonifaci; Fina Climent; María Teresa Soler; Alejo Rodríguez-Vida; Miguel Gil; Joan Brunet; Griselda Martrat; Laia Gómez-Baldó; Ana I Extremera; Agnes Figueras; Josep Balart; Robert Clarke; Kerry L Burnstein; Kathryn E Carlson; John A Katzenellenbogen; Miguel Vizoso; Manel Esteller; Alberto Villanueva; Ana B Rodríguez-Peña; Xosé R Bustelo; Yusuke Nakamura; Hitoshi Zembutsu; Olle Stål; Roderick L Beijersbergen; Miguel Angel Pujana
Journal:  Breast Cancer Res       Date:  2014-05-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.